$ADVM Strange...."Given the encouraging robust anatomical response from patients in the first cohort, we will begin dosing patients in the second cohort at a lower dose of 2 x 10^11 vg/eye, instead of dose escalating as previously planned.”
This has to be the most clever way to continue a clinical trial without escaping clinical hold, while disguising it as a release off of clinical hold, that I've ever seen...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.